Quercefit® : a registered extract of quercetin in phytosomal form, with clinically proven efficacy
Quercetin is the most active of the natural flavonoids. It is present in large quantities in fruit and vegetables, dark chocolate and green tea. Quercetin has many properties, including antioxidant and anti-inflammatory properties.
Quercefit® is a proprietary extract of quercetin from Sophora japonica L., microencapsulated in phospholipids in phytosomal form. Each phospholipid is associated with a quercetin molecule to form phytosomes.
The phytosomal form facilitates the transport of quercetin and ensures its controlled release within the cells, guaranteeing optimised bioavailability, 20 times greater than that of a standard extract.
A pharmacokinetic study of 8 patients supplemented with either 500 mg of standard quercetin or 500 mg of Quercefit® quercetin demonstrated this bioavailability1.
Several clinical studies have also confirmed the efficacy of Quercefit® quercetin extract. In particular, it is recognised for its ability to :
-
Modulating inflammation and the cytokine cascade in Covid-19, in particular through its senolytic functions2,3;
-
Increase viral clearance, reduce the onset of symptoms and reduce biomarkers associated with the risk of complications in Covid-19 infection4 ;
-
Reduce allergy symptoms (itchy eyes, sneezing, runny nose and trouble sleeping)5 ;
-
Maintain good respiratory function in the event of mild and persistent discomfort during allergic periods6 ;
-
Increase physical performance and reduce recovery time after exercise7;
-
Reduce discomfort during physical activity7;
-
Reduce the oxidative stress generated by exercise7.
Quercefit® is a trademark of INDENA S.p.A, Italy
(1) Riva A., et al. Eur J Drug Metab Pharmacokinet, 2019; 44(2): 169-177.
(2) Di Pierro et al., International Journal of General Medicine 2021:14 2359–2366.
(3) Di Pierro et al., International Journal of General Medicine 2021:14 2807–2816.
(4) Rondanelli, M. et al. Life 12.1 (2022): 66
(5) Yamada S. et al., Eur Rev Med Pharmacol Sci. 2022 Jun;26(12):4331-4345.
(6) Riva A. et al., Minerva Cardioangiol. 2018 Sep 13. doi: 10.23736/S0026-4725.18.04795-3.
(7) Riva A. et al., Minerva Medica 2018 august;109(4):285-9